RSV in transplant and immunocompromised patients #MMPMID39231600
Koval CE; Gonzalez BE
Cleve Clin J Med 2024[Sep]; 91 (9 suppl 1): S34-S41 PMID39231600show ga
Respiratory syncytial virus (RSV) is a significant cause of morbidity and mortality in infants, older adults, and patients with weakened immune systems. Disease severity differs by underlying immunologic pathologies, with worse outcomes associated with progression from upper to lower respiratory disease. In this review we address the impact of RSV in immunocompromised populations, and discuss the limited available treatments and the potential impact of newer RSV prevention strategies on immunocompromised adults and children.